An observational study in Von Hippel Lindau Disease, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in von Hippel-Lindau Disease with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. von Hippel-Lindau Disease · United States.
Among the 33 studies in von Hippel-Lindau Disease with a site in United States, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2023, is one of 10 observational ones, and was the 32nd registered.
55 studies on the registry are indexed under von Hippel-Lindau Disease; 23 are open to participants now.
Browse von Hippel-Lindau Disease studies →8 of the 33 studies in von Hippel-Lindau Disease with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 19 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Canada and 19 more countries
Ages 12+
National Cancer Institute (NCI) · Sites in United States
Ages 12+
St. Jude Children's Research Hospital · Sites in United States
National Eye Institute (NEI) · Sites in United States
Ages 2–120 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 von Hippel-Lindau Disease studies recruiting now, 16 (80%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 1
First in 1997; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 260 across 23 observational studies indexed under von Hippel-Lindau Disease.
Median enrollment 15 across the 23 interventional studies, 300 across the 10 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 5 studies filed under von Hippel-Lindau Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in von Hippel-Lindau Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05955014M.D. Anderson Cancer CenterData Collection Protocol for Patients With Von Hippel Lindau Disease | 2026-12-31 |
| NCT03401788Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | 2027-04-29 |
| NCT05737602Massachusetts General HospitalPromoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in von Hippel-Lindau Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
Primary Objectives:
Secondary Objectives:
--Obtain quality of life data in patients with vHL disease
M D Anderson Cancer Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression-free survival (PFS)
Time frame: through study completion; an average of 1 year
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.